Subxiphoid Thoracoscopic Surgery Is Safe and Feasible for the Treatment of Anterior Mediastinal Teratomas: A Multicentre Retrospective Study

剑突下胸腔镜手术治疗前纵隔畸胎瘤安全可行:一项多中心回顾性研究

阅读:1

Abstract

BACKGROUND: Mediastinal benign teratoma is rare, with surgery being the only effective treatment. Few studies reported the surgical outcomes of resecting mediastinal benign teratomas via the subxiphoid approach by thoracoscopy. This study retrospectively compares the subxiphoid with other surgical approaches, aiming to assess the safety and feasibility of this technique. METHODS: We retrospectively analysed the clinical data of 159 patients with pathologically confirmed mediastinal benign teratomas who underwent surgery in 5 hospitals from July 2014 to June 2024. Various parameters of the subxiphoid approach were compared with those of other surgical methods. RESULTS: The surgical approaches included median sternotomy in 26 cases, lateral thoracotomy in 14 cases, lateral thoracoscopic surgery in 80 cases, subxiphoid thoracoscopic surgery in 26 cases, and robotic surgery in 13 cases. For patients who underwent the subxiphoid approach, the median surgery time was 80 min (70, 90), the median intraoperative blood loss was 20 mL (10, 20), the median postoperative drainage volume was 200 mL (0, 350), and the median time to drain removal was 3 days (0, 3). Complete tumour resection was achieved in all 26 patients (100%). The subxiphoid approach showed advantages in the aforementioned aspects compared to other surgical methods. CONCLUSIONS: The subxiphoid and subcostal arch approach is a safe and feasible surgical technique for benign anterior mediastinal teratoma, with a potentially faster postoperative recovery and less cost. It is a valuable alternative to conventional median sternotomy, lateral thoracotomy, and lateral thoracoscopic surgery in resection of anterior mediastinal teratoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。